Lidocaine Injection Recalled – Particle Matter
About the Lidocaine Injection Recall
According to the U.S. Food and Drug Administration (FDA), Hospira has recalled the injection because the product is discolored.
There are visible particles in the solution and attached to the glass container. These particles have been identified as iron oxide. No injuries or other health problems have been reported.
Customers are recommended to stop using the injection immediately. Hospira plans to notify its distributers/customers directly via mail.
Medical Effects of Using the Recalled Lidocaine Injection
Netdoctor (netdoctor.com) states that the Lidocaine HCl injection is used as a local anesthetic or as an emergency treatment for heart rhythm problems. It works by temporarily blocking the pathway of pain signals along nerves.
If the recalled Lidocaine injection was used (depending on the particle size and number), it could block drug administration to the patient, potentially hindering treatment. It could also result in local inflammation, medical disruption of tissue or immune response to the particulate. An extremely rare case may result in severe tissue damage.
If a customer experiences any problems, Hospira can be reached at 1-800-441-4100 (M-F, 8am to 5pm CT) or at ProductComplaintsPP@hospira.com. A report may also be made the FDA’s MedWatch Adverse Event Reporting Program.
Description of Recalled Lidocaine Injection
- The injection recalled is the Lidocaine HCI Injection, USP, 2%, 20 mg per mL, 5 mL single-Dose Vial, Preservative-Free (NDC 0409-2066-05; Lot 25-550-DD, Expiry 1JAN2015).
- Particulate matter attached to the glass container was caused by supplier’s glass defect.
- Lidocaine is packaged 10 units per carton / 180 units per case in single-dose glass fliptop vials.
- The recalled lot was distributed nationwide to distributors/wholesalers, hospitals and clinics from June 2013 to July 2013.